Metabolon Unveils New Integrated Bioinformatics Platform
MORRISVILLE, N.C., Feb. 29, 2024 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, today announced at Biomarkers UK the launch of its latest innovation: an integrated bioinformatics platform, advancing the landscape for metabolomics analysis in life sciences research.
- Partial Least Squares–Discriminant Analysis (PLS-DA): Facilitates the interpretation of complex datasets, enabling the identification of distinctive biomarkers that drive group separation.
- "Metabolon has developed a solid, scalable solution to the non-trivial problem of metabolomics biochemical interpretation, specifically tailored to their world-leading data acquisition platform.
- Metabolon's new bioinformatics platform alleviates much of this manual burden, with client data pre-populated and ready for analysis, accelerating discovery with publication-ready charts, plots, data tables, and insights.
- "Metabolon is thrilled to unveil this groundbreaking bioinformatics platform, marking a significant leap forward in metabolomics research," said Dr. Ray Moran, Senior Director of Bioinformatics at Metabolon.